Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Determinants of anti-PD1 response and resistance in clear cell renal cell carcinoma

Lewis Au, Emine Hatipoglu, Marc Robert de Massy, View ORCID ProfileKevin Litchfield, Andrew Rowan, Rachael Thompson, Desiree Schnidrig, Fiona Byrne, Gordon Beattie, Stuart Horswell, Nicos Fotiadis, Steve Hazell, David Nicol, Scott Thomas Colville Shepherd, Annika Fendler, Robert Mason, Jan Attig, Kroopa Joshi, Imran Uddin, Pablo Becker, Mariana Werner Sunderland, Ayse Akarca, Ignazio Puccio, William Yang, Tom Lund, Kim Dhillon, Marcos Duran Vasquez, Ehsan Ghorani, Hang Xu, José Ignacio López, Anna Green, Ula Mahadeva, Elaine Borg, Miriam Mitchison, David Moore, Ian Proctor, Mary Falzon, Andrew Furness, Lisa Pickering, James L. Reading, Roberto Salgado, Teresa Marafioti, Mariam Jamal-Hanjani, George Kassiotis, Benny Chain, James Larkin, Charles Swanton, Sergio A Quezada, Samra Turajlic on behalf of the PEACE Consortium, on behalf of the TRACERx Renal Consortium
doi: https://doi.org/10.1101/2021.03.19.21253661
Lewis Au
1Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK
2Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emine Hatipoglu
2Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK
3Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London WC1E 6DD, UK
4Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Robert de Massy
3Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London WC1E 6DD, UK
4Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin Litchfield
5Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kevin Litchfield
Andrew Rowan
5Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachael Thompson
6Retroviral Immunology, The Francis Crick Institute, London NW1 1AT, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Desiree Schnidrig
1Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fiona Byrne
1Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gordon Beattie
3Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London WC1E 6DD, UK
4Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stuart Horswell
7Department of Bioinformatics and Biostatistics, The Francis Crick Institute, London NW1 1AT, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicos Fotiadis
8Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden Hospital, London SW3 6JJ, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steve Hazell
9Department of Pathology, the Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Nicol
10Department of Urology, the Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott Thomas Colville Shepherd
1Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK
2Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annika Fendler
1Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Mason
2Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan Attig
6Retroviral Immunology, The Francis Crick Institute, London NW1 1AT, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kroopa Joshi
3Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London WC1E 6DD, UK
4Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Imran Uddin
3Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London WC1E 6DD, UK
4Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pablo Becker
3Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London WC1E 6DD, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mariana Werner Sunderland
3Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London WC1E 6DD, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ayse Akarca
11Department of Cellular Pathology, University College London Hospital, London NW1 2BU, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ignazio Puccio
11Department of Cellular Pathology, University College London Hospital, London NW1 2BU, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Yang
11Department of Cellular Pathology, University College London Hospital, London NW1 2BU, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tom Lund
11Department of Cellular Pathology, University College London Hospital, London NW1 2BU, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kim Dhillon
11Department of Cellular Pathology, University College London Hospital, London NW1 2BU, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcos Duran Vasquez
3Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London WC1E 6DD, UK
4Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ehsan Ghorani
3Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London WC1E 6DD, UK
4Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hang Xu
5Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
José Ignacio López
12Department of Pathology, Cruces University Hospital, Biocruces-Bizkaia Institute, 48903 Barakaldo, Bizkaia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Green
13Department of Cellular Pathology, Guy’s & St Thomas’ NHS Foundation Trust, St Thomas’ Hospital, London SE1 7EH, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ula Mahadeva
13Department of Cellular Pathology, Guy’s & St Thomas’ NHS Foundation Trust, St Thomas’ Hospital, London SE1 7EH, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elaine Borg
11Department of Cellular Pathology, University College London Hospital, London NW1 2BU, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miriam Mitchison
11Department of Cellular Pathology, University College London Hospital, London NW1 2BU, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Moore
4Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK
11Department of Cellular Pathology, University College London Hospital, London NW1 2BU, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian Proctor
11Department of Cellular Pathology, University College London Hospital, London NW1 2BU, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary Falzon
11Department of Cellular Pathology, University College London Hospital, London NW1 2BU, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Furness
2Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa Pickering
2Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James L. Reading
3Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London WC1E 6DD, UK
4Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roberto Salgado
14Division of Research, Peter MacCallum Cancer Centre, Melbourne VIC300, Australia
15Department of Pathology, GZA-ZNA Hospitals, Wilrijk, Antwerp, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teresa Marafioti
11Department of Cellular Pathology, University College London Hospital, London NW1 2BU, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mariam Jamal-Hanjani
4Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK
16Cancer Metastasis Laboratory, University College London Cancer Institute, London WC1E 6DD, UK
17Department of Medical Oncology, University College London Hospitals, London NW1 2BU, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George Kassiotis
6Retroviral Immunology, The Francis Crick Institute, London NW1 1AT, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benny Chain
18Division of Infection and Immunity, University College London, London WC1E 6BT, UK
19University College London Cancer Institute, London WC1E 6DD, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Larkin
2Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles Swanton
4Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK
5Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK
18Division of Infection and Immunity, University College London, London WC1E 6BT, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sergio A Quezada
3Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London WC1E 6DD, UK
4Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: samra.turajlic@crick.ac.uk s.quezada@ucl.ac.uk
Samra Turajlic
1Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK
2Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: samra.turajlic@crick.ac.uk s.quezada@ucl.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Summary

Antigen recognition and T-cell mediated cytotoxicity in clear-cell renal cell carcinoma (ccRCC) remains incompletely understood. To address this knowledge gap, we analysed 115 multiregion tumour samples collected from 15 treatment-naïve patients pre- and post-nivolumab therapy, and at autopsy in three patients. We performed whole-exome sequencing, RNAseq, TCRseq, multiplex immunofluorescence and flow cytometry analyses and correlated with clinical response. We observed pre-treatment intratumoural TCR clonal expansions suggesting pre-existing immunity. Nivolumab maintained pre-treatment expanded, clustered TCR clones in responders, suggesting ongoing antigen-driven stimulation of T-cells. T-cells in responders were enriched for expanded TCF7+CD8+ T-cells and upregulated GZMK/B upon nivolumab-binding. By contrast, nivolumab promoted accumulation of new TCR clones in non-responders, replacing pre-treatment expanded clonotypes. In this dataset, mutational features did not correlate with response to nivolumab and human endogenous retrovirus expression correlated indirectly. Our data suggests that nivolumab potentiates clinical responses in ccRCC by binding pre-existing expanded CD8+ T-cells to enhance cytotoxicity.

Competing Interest Statement

L.A. is funded by the Royal Marsden Cancer Charity. J.A. is a full-time employee of Hoffmann-La Roche AG (Basel, Switzerland). L.P. has received research funding from Pierre Fabre, and honoria from Pfizer, Ipsen, Bristol-Myers Squibb, and EUSA Pharma. S.T. is funded by Cancer Research UK (C50947/A18176), the National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden Hospital and Institute of Cancer Research (A109), the Kidney and Melanoma Cancer Fund of The Royal Marsden Cancer Charity, The Rosetrees Trust (A2204), Ventana Medical Systems Inc (10467/10530), the National Institute of Health (US) and the Melanoma Research Alliance. R.S. has received non-financial support from Merck and Bristol Myers Squibb, research support from Merck, Puma Biotechnology, and Roche; and advisory board fees for Bristol Myers Squibb; and personal fees from Roche for an advisory board related to a trial-research project; all related to breast cancer research projects. R.S. reports no conflict of interests related to this project. G.K. receives core funding from the Francis Crick Institute (FC0010099). M.J.H. is a Cancer Research UK (CRUK) Clinician Scientist (RCCFEL\100099) and has received funding from CRUK, National Institute for Health Research, Rosetrees Trust, UKI NETs and NIHR University College London Hospitals Biomedical Research Centre. M.J.H. is a member of the Scientific Advisory Board and Steering Committee for Achilles Therapeutics. J.L. has received research funding from Bristol-Myers Squibb, Merck, Novartis, Pfizer, Achilles Therapeutics, Roche, Nektar Therapeutics, Covance, Immunocore, Pharmacyclics, and Aveo, and served as a consultant to Achilles, AstraZeneca, Boston Biomedical, Bristol-Myers Squibb, Eisai, EUSA Pharma, GlaxoSmithKline, Ipsen, Imugene, Incyte, iOnctura, Kymab, Merck Serono, Nektar, Novartis, Pierre Fabre, Pfizer, Roche Genentech, Secarna, and Vitaccess. C.S. acknowledges grant support from Pfizer, AstraZeneca, Bristol-Myers Squibb, Roche-Ventana, Boehringer-Ingelheim, Archer Dx Inc (collaboration in minimal residual disease sequencing technologies) and Ono Pharmaceutical, is an AstraZeneca Advisory Board member and Chief Investigator for the MeRmaiD1 clinical trial, has consulted for Pfizer, Novartis, GlaxoSmithKline, MSD, Bristol-Myers Squibb, Celgene, AstraZeneca, Illumina, Genentech, Roche-Ventana, GRAIL, Medicxi, Bicycle Therapeutics, and the Sarah Cannon Research Institute, has stock options in Apogen Biotechnologies, Epic Bioscience, GRAIL, and has stock options and is co-founder of Achilles Therapeutics. Patents: C.S. holds European patents relating to assay technology to detect tumour recurrence (PCT/GB2017/053289); to targeting neoantigens (PCT/EP2016/059401), identifying patent response to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004), predicting survival rates of patients with cancer (PCT/GB2020/050221), identifying patients who respond to cancer treatment (PCT/GB2018/051912), a US patent relating to detecting tumour mutations (PCT/US2017/28013) and both a European and US patent related to identifying insertion/deletion mutation targets (PCT/GB2018/051892). C.S. is Royal Society Napier Research Professor (RP150154). His work is supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001169), the UK Medical Research Council (FC001169), and the Wellcome Trust (FC001169). C.S. is funded by Cancer Research UK (TRACERx, PEACE and CRUK Cancer Immunotherapy Catalyst Network), Cancer Research UK Lung Cancer Centre of Excellence, the Rosetrees Trust, Butterfield and Stoneygate Trusts, NovoNordisk Foundation (ID16584), Royal Society Research Professorship Enhancement Award (RP/EA/180007), the NIHR BRC at University College London Hospitals, the CRUK-UCL Centre, Experimental Cancer Medicine Centre and the Breast Cancer Research Foundation, USA (BCRF). His research is supported by a Stand Up To Cancer-LUNGevity-American Lung Association Lung Cancer Interception Dream Team Translational Research Grant (SU2C-AACR-DT23-17). Stand Up To Cancer is a program of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the Scientific Partner of SU2C. C.S. also receives funding from the European Research Council (ERC) under the European Unions Seventh Framework Programme (FP7/2007-2013) Consolidator Grant (FP7-THESEUS-617844), European Commission ITN (FP7-PloidyNet 607722), an ERC Advanced Grant (PROTEUS) from the European Research Council under the European Unions Horizon 2020 research and innovation programme (835297) and Chromavision from the European Unions Horizon 2020 research and innovation programme (665233). ST has received speaking fees from Roche, Astra Zeneca, Novartis and Ipsen. ST has the following patents filed: Indel mutations as a therapeutic target and predictive biomarker PCTGB2018/051892 and PCTGB2018/051893 and Clear Cell Renal Cell Carcinoma Biomarkers P113326GB.

Clinical Trial

NCT02446860

Funding Statement

The ADAPTeR study (CA209-129) is sponsored by The Royal Marsden NHS Foundation Trust, and partly funded by National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at the Royal Marsden Hospital and Institute of Cancer Research (ICR) (A80), and Cancer Research UK (CRUK) (17767). Bristol-Myers Squibb was the drug provider. The Francis Crick Institute, which receives its core funding from CRUK (FC010110), the UK Medical Research Council (FC010110), the Wellcome Trust (FC010110). For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. TRACERx Renal is funded by NIHR BRC at the Royal Marsden Hospital and Institute of Cancer Research (A109).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

ADAPTeR (NCT02446860) was initially approved by NRES Committee London Fulham on 01/12/2014. ADAPTeR is performed in accordance with the ethical principles in the Declaration of Helsinki, Good Clinical Practice and applicable regulatory requirements.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* Lead Contact

Data Availability

Further information and requests for resources, data and reagents should be directed to and will be fulfilled by the Lead Contact, Samra Turajlic (samra.turajlic@crick.ac.uk).

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted March 28, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Determinants of anti-PD1 response and resistance in clear cell renal cell carcinoma
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Determinants of anti-PD1 response and resistance in clear cell renal cell carcinoma
Lewis Au, Emine Hatipoglu, Marc Robert de Massy, Kevin Litchfield, Andrew Rowan, Rachael Thompson, Desiree Schnidrig, Fiona Byrne, Gordon Beattie, Stuart Horswell, Nicos Fotiadis, Steve Hazell, David Nicol, Scott Thomas Colville Shepherd, Annika Fendler, Robert Mason, Jan Attig, Kroopa Joshi, Imran Uddin, Pablo Becker, Mariana Werner Sunderland, Ayse Akarca, Ignazio Puccio, William Yang, Tom Lund, Kim Dhillon, Marcos Duran Vasquez, Ehsan Ghorani, Hang Xu, José Ignacio López, Anna Green, Ula Mahadeva, Elaine Borg, Miriam Mitchison, David Moore, Ian Proctor, Mary Falzon, Andrew Furness, Lisa Pickering, James L. Reading, Roberto Salgado, Teresa Marafioti, Mariam Jamal-Hanjani, George Kassiotis, Benny Chain, James Larkin, Charles Swanton, Sergio A Quezada, Samra Turajlic
medRxiv 2021.03.19.21253661; doi: https://doi.org/10.1101/2021.03.19.21253661
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Determinants of anti-PD1 response and resistance in clear cell renal cell carcinoma
Lewis Au, Emine Hatipoglu, Marc Robert de Massy, Kevin Litchfield, Andrew Rowan, Rachael Thompson, Desiree Schnidrig, Fiona Byrne, Gordon Beattie, Stuart Horswell, Nicos Fotiadis, Steve Hazell, David Nicol, Scott Thomas Colville Shepherd, Annika Fendler, Robert Mason, Jan Attig, Kroopa Joshi, Imran Uddin, Pablo Becker, Mariana Werner Sunderland, Ayse Akarca, Ignazio Puccio, William Yang, Tom Lund, Kim Dhillon, Marcos Duran Vasquez, Ehsan Ghorani, Hang Xu, José Ignacio López, Anna Green, Ula Mahadeva, Elaine Borg, Miriam Mitchison, David Moore, Ian Proctor, Mary Falzon, Andrew Furness, Lisa Pickering, James L. Reading, Roberto Salgado, Teresa Marafioti, Mariam Jamal-Hanjani, George Kassiotis, Benny Chain, James Larkin, Charles Swanton, Sergio A Quezada, Samra Turajlic
medRxiv 2021.03.19.21253661; doi: https://doi.org/10.1101/2021.03.19.21253661

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (504)
  • Anesthesia (110)
  • Cardiovascular Medicine (1240)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (531)
  • Epidemiology (10023)
  • Forensic Medicine (5)
  • Gastroenterology (499)
  • Genetic and Genomic Medicine (2454)
  • Geriatric Medicine (238)
  • Health Economics (479)
  • Health Informatics (1644)
  • Health Policy (753)
  • Health Systems and Quality Improvement (636)
  • Hematology (248)
  • HIV/AIDS (533)
  • Infectious Diseases (except HIV/AIDS) (11865)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (252)
  • Medical Ethics (75)
  • Nephrology (268)
  • Neurology (2281)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (537)
  • Oncology (1245)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (730)
  • Pharmacology and Therapeutics (313)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2281)
  • Public and Global Health (4834)
  • Radiology and Imaging (837)
  • Rehabilitation Medicine and Physical Therapy (492)
  • Respiratory Medicine (651)
  • Rheumatology (285)
  • Sexual and Reproductive Health (238)
  • Sports Medicine (227)
  • Surgery (267)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)